Dapsone Prurigo Study
Primary Purpose
Lichen Simples Chronicus and Prurigo
Status
Unknown status
Phase
Not Applicable
Locations
United States
Study Type
Interventional
Intervention
Dapsone gel - verum
Sponsored by
About this trial
This is an interventional treatment trial for Lichen Simples Chronicus and Prurigo focused on measuring lichen simplex chronicus, prurigo
Eligibility Criteria
Inclusion Criteria:
• Active prurigo nodularis or lichen simplex chronicus - diagnosed by clinical exam
- For lichen simplex chronicus patients: Severity of maximum pruritus in the last 24 hrs at least 5 out of 10 on a visual analogue scale.
- For prurigo nodularis patients: Excoriations or signs of other scratch related activity at presentation to demonstrate active disease
- Symmetrical disease/excoriations allowing for a side-by-side comparison (eg, bilateral lichen simplex chronicus or bilateral prurigo nodularis) - genitals, face, axillae or neck cannot be used for side-to-side comparison
- Willing to refrain from use of all other topical medications in the treatment areas.
- Able and willing to provide written informed consent
- Willing and able to understand and comply with the requirements of the study, apply the treatment combinations as instructs, attend required study visits, comply with study prohibitions and able to complete the study.
- Male or non-preganant, non-lactating female between 18 and 75 years of age, inclusive
- For females of child-bearing potential, willing to use adequate birth control during the study conduct
Exclusion Criteria:
• History of non-compliance with follow up visits
- Should we exclude failure to certain treatments as an exclusion criterion? Patients who failed oral dapsone should be excluded
- Presence of any skin condition on the treatment areas that would interfere with the diagnosis or assessment of active lichen simplex chronicus and/or prurigo nodularis (eg, rosacea, dermatitis, psoriasis, squamous cell carcinoma, eczema, acneform eruptions caused by medications, steroid acne, steroid folliculitis or bacterial folliculitis)
- Excessive hair in the treatment area that would interfere with diagnosis or assessment of lichen simplex chronicus and/or prurigo nodularis
- History of hypersensitivity or allergy to topical steroids, dapsone, or any other treatment product components
- Use of tanning booths, sunbathing or excessive exposure to the sun during the study
- Consumes excessive amount of alcohol, abuses drugs, or has any condition that would compromise compliance with this protocol
Sites / Locations
- J H Stroger Hospital of Cook County
Arms of the Study
Arm 1
Arm 2
Arm Type
Active Comparator
Placebo Comparator
Arm Label
dapsone gel - verum
dapsone gel - vehicle only
Arm Description
dapsone gel - verum
Outcomes
Primary Outcome Measures
Pruritus based on visual analogue scale in side to side comparison
Secondary Outcome Measures
5 D itch scale in side to side comparison
Full Information
1. Study Identification
Unique Protocol Identification Number
NCT01870050
Brief Title
Dapsone Prurigo Study
Official Title
A Double-blind, Randomized, Parallel-group, Side-by-side Single-center Study Comparing a Topical Steroid / Vehicle Combination to a Topical Steroid / Topical Dapsone Combination in Patients With Lichen Simplex Chronicus and/or Prurigo Nodularis
Study Type
Interventional
2. Study Status
Record Verification Date
June 2013
Overall Recruitment Status
Unknown status
Study Start Date
September 2013 (undefined)
Primary Completion Date
November 2019 (Anticipated)
Study Completion Date
November 2019 (Anticipated)
3. Sponsor/Collaborators
Responsible Party, by Official Title
Principal Investigator
Name of the Sponsor
Cook County Health
4. Oversight
Data Monitoring Committee
No
5. Study Description
Brief Summary
Principal aim of this study is to assess whether a combination of topical dapsone and clobetasol as a topical steroid is superior to clobetasol alone as treatment of prurigo nodularis or lichen simplex chronicus in a side to side comparison. The study is primarily exploratory and essentially meant to inform the sponsor whether further development of a combination treatment formulation is warranted
6. Conditions and Keywords
Primary Disease or Condition Being Studied in the Trial, or the Focus of the Study
Lichen Simples Chronicus and Prurigo
Keywords
lichen simplex chronicus, prurigo
7. Study Design
Primary Purpose
Treatment
Study Phase
Not Applicable
Interventional Study Model
Single Group Assignment
Masking
ParticipantCare ProviderInvestigatorOutcomes Assessor
Allocation
Randomized
Enrollment
20 (Anticipated)
8. Arms, Groups, and Interventions
Arm Title
dapsone gel - verum
Arm Type
Active Comparator
Arm Description
dapsone gel - verum
Arm Title
dapsone gel - vehicle only
Arm Type
Placebo Comparator
Intervention Type
Drug
Intervention Name(s)
Dapsone gel - verum
Other Intervention Name(s)
aczone gel
Primary Outcome Measure Information:
Title
Pruritus based on visual analogue scale in side to side comparison
Time Frame
8 weeks
Secondary Outcome Measure Information:
Title
5 D itch scale in side to side comparison
Time Frame
8 weeks
10. Eligibility
Sex
All
Minimum Age & Unit of Time
18 Years
Accepts Healthy Volunteers
No
Eligibility Criteria
Inclusion Criteria:
• Active prurigo nodularis or lichen simplex chronicus - diagnosed by clinical exam
For lichen simplex chronicus patients: Severity of maximum pruritus in the last 24 hrs at least 5 out of 10 on a visual analogue scale.
For prurigo nodularis patients: Excoriations or signs of other scratch related activity at presentation to demonstrate active disease
Symmetrical disease/excoriations allowing for a side-by-side comparison (eg, bilateral lichen simplex chronicus or bilateral prurigo nodularis) - genitals, face, axillae or neck cannot be used for side-to-side comparison
Willing to refrain from use of all other topical medications in the treatment areas.
Able and willing to provide written informed consent
Willing and able to understand and comply with the requirements of the study, apply the treatment combinations as instructs, attend required study visits, comply with study prohibitions and able to complete the study.
Male or non-preganant, non-lactating female between 18 and 75 years of age, inclusive
For females of child-bearing potential, willing to use adequate birth control during the study conduct
Exclusion Criteria:
• History of non-compliance with follow up visits
Should we exclude failure to certain treatments as an exclusion criterion? Patients who failed oral dapsone should be excluded
Presence of any skin condition on the treatment areas that would interfere with the diagnosis or assessment of active lichen simplex chronicus and/or prurigo nodularis (eg, rosacea, dermatitis, psoriasis, squamous cell carcinoma, eczema, acneform eruptions caused by medications, steroid acne, steroid folliculitis or bacterial folliculitis)
Excessive hair in the treatment area that would interfere with diagnosis or assessment of lichen simplex chronicus and/or prurigo nodularis
History of hypersensitivity or allergy to topical steroids, dapsone, or any other treatment product components
Use of tanning booths, sunbathing or excessive exposure to the sun during the study
Consumes excessive amount of alcohol, abuses drugs, or has any condition that would compromise compliance with this protocol
Central Contact Person:
First Name & Middle Initial & Last Name or Official Title & Degree
Joerg Albrecht, MD
Phone
3128644480
Email
jalbrecht@cookcountyhhs.org
Overall Study Officials:
First Name & Middle Initial & Last Name & Degree
Joerg Albrecht, MD
Organizational Affiliation
J.H.Stroger Hospital of Cook County
Official's Role
Principal Investigator
Facility Information:
Facility Name
J H Stroger Hospital of Cook County
City
Chicago
State/Province
Illinois
ZIP/Postal Code
60612
Country
United States
Facility Contact:
First Name & Middle Initial & Last Name & Degree
Joerg Albrecht, MD
Phone
312-864-4480
Email
jalbrecht@cookcountyhhs.org
First Name & Middle Initial & Last Name & Degree
Joerg Albrecht
First Name & Middle Initial & Last Name & Degree
Warren Piette, MD
12. IPD Sharing Statement
Learn more about this trial
Dapsone Prurigo Study
We'll reach out to this number within 24 hrs